Antiproliferative Mechanisms of Metformin in Breast Cancer: A Systematic Review of the Literature

Overview

Journal Int J Mol Sci

Publisher MDPI

Date 2025 Jan 11

PMID 39796103

Authors

Aiman Moldasheva

Assem Zhakupova

Mohamad Aljofan

Affiliations

Soon will be listed here.

Abstract

Metformin is an antidiabetic drug with reported potential antiproliferative activity against different cancer types including breast cancer. However, the mechanism of action of how metformin can induce its antiproliferative activity is still unclear. Thus, the current study is a systematic review of the literature aiming to explore the reported antiproliferative mechanisms of metformin against breast cancer. The study included seventeen research articles that describe different mechanisms of action against breast cancer. While the majority of the studies confirm the antiproliferative potential of metformin, albeit at different potencies, there appear to be various mechanisms and factors that can influence this effect. There are a number of questions yet to be answered pertaining the use of metformin as an anti-cancer agent, warranting further investigation into this emerging area of research.

References

Soukas A, Hao H, Wu L . Metformin as Anti-Aging Therapy: Is It for Everyone?. Trends Endocrinol Metab. 2019; 30(10):745-755. PMC: 6779524. DOI: 10.1016/j.tem.2019.07.015. View

Cabello P, Pineda B, Tormo E, Lluch A, Eroles P . The Antitumor Effect of Metformin Is Mediated by miR-26a in Breast Cancer. Int J Mol Sci. 2016; 17(8). PMC: 5000695. DOI: 10.3390/ijms17081298. View

Kim N, Lee H, Lee C . Metformin targets Axl and Tyro3 receptor tyrosine kinases to inhibit cell proliferation and overcome chemoresistance in ovarian cancer cells. Int J Oncol. 2015; 47(1):353-60. DOI: 10.3892/ijo.2015.3004. View

Yari S, Khoei H, Saber M, Esfandiari F, Moini A, Shahhoseini M . Metformin attenuates expression of angiogenic and inflammatory genes in human endometriotic stromal cells. Exp Cell Res. 2021; 404(2):112659. DOI: 10.1016/j.yexcr.2021.112659. View

Lim S, Jin L, Luo K, Jin J, Shin Y, Hong S . Klotho enhances FoxO3-mediated manganese superoxide dismutase expression by negatively regulating PI3K/AKT pathway during tacrolimus-induced oxidative stress. Cell Death Dis. 2017; 8(8):e2972. PMC: 5596554. DOI: 10.1038/cddis.2017.365. View

Tan M, Wu A, Liao N, Liu M, Guo Q, Yi J . Inhibiting ROS-TFE3-dependent autophagy enhances the therapeutic response to metformin in breast cancer. Free Radic Res. 2018; 52(8):872-886. DOI: 10.1080/10715762.2018.1485075. View

Alalem M, Ray A, Ray B . Metformin induces degradation of mTOR protein in breast cancer cells. Cancer Med. 2016; 5(11):3194-3204. PMC: 5119975. DOI: 10.1002/cam4.896. View

Zhang Y, Swanda R, Nie L, Liu X, Wang C, Lee H . mTORC1 couples cyst(e)ine availability with GPX4 protein synthesis and ferroptosis regulation. Nat Commun. 2021; 12(1):1589. PMC: 7952727. DOI: 10.1038/s41467-021-21841-w. View

Moroishi T, Park H, Qin B, Chen Q, Meng Z, Plouffe S . A YAP/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis. Genes Dev. 2015; 29(12):1271-84. PMC: 4495398. DOI: 10.1101/gad.262816.115. View

10.

Pasquali R, Renato P . Metformin in women with PCOS, pros. Endocrine. 2014; 48(2):422-6. DOI: 10.1007/s12020-014-0311-1. View

11.

Hou Y, Cai S, Yu S, Lin H . Metformin induces ferroptosis by targeting miR-324-3p/GPX4 axis in breast cancer. Acta Biochim Biophys Sin (Shanghai). 2021; 53(3):333-341. DOI: 10.1093/abbs/gmaa180. View

12.

Saraei P, Asadi I, Azam Kakar M, Moradi-Kor N . The beneficial effects of metformin on cancer prevention and therapy: a comprehensive review of recent advances. Cancer Manag Res. 2019; 11:3295-3313. PMC: 6497052. DOI: 10.2147/CMAR.S200059. View

13.

Shi P, Liu W, Tala , Wang H, Li F, Zhang H . Metformin suppresses triple-negative breast cancer stem cells by targeting KLF5 for degradation. Cell Discov. 2017; 3:17010. PMC: 5396048. DOI: 10.1038/celldisc.2017.10. View

14.

Queiroz E, Puukila S, Eichler R, Sampaio S, Forsyth H, Lees S . Metformin induces apoptosis and cell cycle arrest mediated by oxidative stress, AMPK and FOXO3a in MCF-7 breast cancer cells. PLoS One. 2014; 9(5):e98207. PMC: 4032293. DOI: 10.1371/journal.pone.0098207. View

15.

Nurzhan S, Bekezhankyzy Z, Ding H, Berdigaliyev N, Sergazy S, Gulyayev A . The Effect of Different Glucose Concentrations on the Antiproliferative Activity of Metformin in MCF-7 Breast Cancer Cells. Pharmaceutics. 2023; 15(9). PMC: 10537756. DOI: 10.3390/pharmaceutics15092186. View

16.

Olzmann J, Li L, Chin L . Aggresome formation and neurodegenerative diseases: therapeutic implications. Curr Med Chem. 2008; 15(1):47-60. PMC: 4403008. DOI: 10.2174/092986708783330692. View

17.

Xu T, Brandmaier S, Messias A, Herder C, Draisma H, Demirkan A . Effects of metformin on metabolite profiles and LDL cholesterol in patients with type 2 diabetes. Diabetes Care. 2015; 38(10):1858-67. DOI: 10.2337/dc15-0658. View

18.

Zhao Y, Yang X . The Hippo pathway in chemotherapeutic drug resistance. Int J Cancer. 2014; 137(12):2767-73. DOI: 10.1002/ijc.29293. View

19.

Martin-Belmonte F, Perez-Moreno M . Epithelial cell polarity, stem cells and cancer. Nat Rev Cancer. 2011; 12(1):23-38. DOI: 10.1038/nrc3169. View

20.

Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J . Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001; 108(8):1167-74. PMC: 209533. DOI: 10.1172/JCI13505. View